Stay updated on Nivolumab in AML Remission at High Risk Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in AML Remission at High Risk Clinical Trial page.
Latest updates to the Nivolumab in AML Remission at High Risk Clinical Trial page
- Check7 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.5%
- Check14 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study, along with the locations where the study is taking place.SummaryDifference3%
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe website has added new features, while several detailed options for data download and participant information have been removed.SummaryDifference4%
- Check36 days agoChange DetectedSeveral links related to leukemia and clinical resources have been removed, including those from MedlinePlus and NIH, which may affect access to important health information.SummaryDifference1%
- Check43 days agoChange DetectedThe website has been updated to version 2.12.2, with numerous new links added related to leukemia and clinical trials, while the previous version 2.12.1 has been removed.SummaryDifference6%
- Check51 days agoChange DetectedThe website has updated its version to v2.12.1, removing the estimated timestamps for 'Results First Posted' and 'Last Update Posted' from the previous version v2.12.0.SummaryDifference0.9%
Stay in the know with updates to Nivolumab in AML Remission at High Risk Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in AML Remission at High Risk Clinical Trial page.